Immune Checkpoint Inhibitors & Gastrointestinal Toxicities: Key Points for the Community Pharmacist

Activity Preview

This training includes an overview of the mechanism of action of immune checkpoint inhibitors (ICIs), associated gastrointestinal immune-related adverse events (irAEs), and when to refer patients to their oncologist for assessment and management of symptoms consistent with irAEs.

  

Learning Objectives

At the completion of this application-based activity, participants will be able to: 

  1. Describe the mechanism of action of immune checkpoint inhibitors.  
  2. Categorize the seven Food and Drug Administration–approved immune checkpoint inhibitors as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors, programmed death-1 (PD-1) inhibitors, or programmed death-ligand (PD-L1) inhibitors.  
  3. Recognize the presenting symptoms of the most common gastrointestinal immune-related adverse events in patients treated with immune checkpoint inhibitors. 
  4. Identify the best questions to ask patients with cancer to determine the symptoms and severity of a potential gastrointestinal immune-related adverse event.  
  5. Discuss when and how to refer patients to their medical oncologist for further work-up.  
Activity type: Knowledge-based

Target Audience: Pharmacists 

Learning Level: 2

Accreditation Information

ACPE Logo

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following archived webinar is approved for 1.0 contact hour of CPE credit (0.1 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-19-295-H01-P.

To obtain credit for completing Immune Checkpoint Inhibitors & Gastrointestinal Toxicities: Key Points for the Community Pharmacistparticipants will need to complete the self-study module, complete the assessment with a grade of 70% or better, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.   

Initial release date: February 18, 2020

Expiration date: February 18, 2023

Development

Immune Checkpoint Inhibitors & Gastrointestinal Toxicities: Key Points for the Community Pharmacist is an activity for pharmacists developed by the American Pharmacists Association.

Disclosures

Lisa Cordes, PharmD, BCACP, BCOP, and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures

Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association.

Fee

There is no fee associated with this member-only activity. 

System Requirements

Computer and internet access are required to complete this activity.  Please visit our website to view the Technology System Requirements in order to have a positive learning experience.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-19-295-H01-P 0.1 CEUs February 18, 2020 - February 18, 2023